In short
Clinical trials are investigating Adenosine in several heart-related conditions, including coronary artery disease, Takotsubo syndrome, microvascular dysfunction, chronic coronary syndrome, CABG-related ischemia, and STEMI. These studies are looking at diagnostic accuracy, blood flow measures, and treatment effects in different patient groups. Most trials are in Phase 2 or Phase 3.
Key points
- Clinical trials of Adenosine are being done in several heart and coronary conditions, especially coronary artery disease, Takotsubo syndrome, chronic coronary syndrome, microvascular dysfunction, and STEMI. The studies include both Phase 2 and Phase 3 trials. Some trials use Adenosine for heart imaging or stress testing, while others study it as part of treatment strategies with other medicines or devices. The main goals are to measure blood flow, heart muscle function, diagnostic accuracy, and recovery after heart injury. The target groups include people with suspected or known heart disease, as well as some people with acute or chronic heart problems. One study also includes healthy subjects for comparison.
Trial overview
These studies investigate Adenosine in heart and blood vessel research, mostly in people with coronary artery disease or related conditions.
The trials are designed to study both diagnosis and treatment-related questions, depending on the condition and the study plan.
Conditions being studied
The trial data includes coronary artery disease, Takotsubo syndrome, coronary microvascular dysfunction (also called CMD), chronic coronary syndrome, chronic angina with left ventricular dysfunction, and STEMI.
One study also includes healthy subjects, so researchers can compare the heart response across different groups.
Study designs and phases
All listed studies are interventional, which means the researchers give a study treatment or study procedure and then measure the results.
The trials are mainly in Phase 2 and Phase 3, showing that the research is focused on testing performance, comparing strategies, and checking clinical effects in larger groups.
Enrollment ranges from 30 people in a small imaging study to 1,600 people in a large treatment study, so the trials vary a lot in size.
Main outcomes being measured
The studies measure different types of outcomes, including diagnostic sensitivity and specificity, which show how well a test finds disease and avoids false results.
Other outcomes include myocardial blood flow, myocardial hyperemia, wall motion score index, left ventricular ejection fraction, ischemic burden, and thromboembolic events such as stroke, peripheral arterial embolization, or myocardial infarction.
Some trials also use imaging methods such as PET, CMR, echocardiography, and transthoracic echocardiography to measure these outcomes.
Who can take part
Participation depends on the study, but the target groups include people with suspected coronary artery disease, known coronary artery disease, Takotsubo syndrome, CMD, chronic coronary syndrome, chronic angina with left ventricular dysfunction, and STEMI after primary PCI.
In the HYPER-trial, the study groups are split into healthy people and patients with suspected or known chronic coronary syndrome, with and without known heart failure.
What the trials aim to learn
Some studies aim to see whether Adenosine helps improve the accuracy of PET imaging or quantitative blood flow measurement in the heart.
Other studies look at whether Adenosine-based strategies can improve heart function, reduce microvascular injury, or improve clinical outcomes after heart events or surgery.
Across the studies, the main goal is to learn how Adenosine can be used in different heart research settings, from diagnosis to recovery and treatment support.